{
  "docId": "019dd923-622c-750b-8b96-9677b0b52fc7",
  "docSlug": "1049581a951f",
  "documentTitle": "Prothena Corp PLC (PRTA)",
  "authorId": "51_Muddy_Waters",
  "authorName": "Carson C. Block",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2017-06-29 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77272725,
  "pageNumber": 9,
  "pageCount": 11,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "overcrowded",
  "nDataPoints": 80,
  "notes": "The slide argues that the exclusion of renal dysfunction patients and the lack of dose-response correlation undermine the reported efficacy of NEOD001.",
  "elementsJson": [
    "paragraph",
    "headline_text",
    "data_table",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b96-9677b0b52fc7/9",
  "deckHref": "/decks/019dd923-622c-750b-8b96-9677b0b52fc7",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b96-9677b0b52fc7.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b96-9677b0b52fc7#slide-9",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "The Phase 3 dose is 24 mg / kg, which implies that PRTA views 0.5 mg / kg to 4.0 mg / kg doses as sub-therapeutic; however, 50% (four out of eight) patients at these doses experienced organ responses, which calls into question whether the responses were due to PCD treatments or NEOD001.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-e6ee-7118-871d-b4e7086f60ad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.28,
        "w": 0.68,
        "x": 0.16,
        "y": 0.47
      },
      "kind": "chart",
      "text": "Patient response heatmap by dose",
      "attrs": null,
      "subkind": "heatmap",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "badafc93-27f8-46c9-b173-f27140c6d885",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "NT-proBNP percentage change",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-e6ee-7118-871d-bb5eadf46c3f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.78,
        "x": 0.11,
        "y": 0.09
      },
      "kind": "paragraph",
      "text": "The second problem with the NEOD001 Best Response Analysis is that it excluded patients with progressive renal dysfunction. It is widely accepted that an improvement in renal function is associated with lower NT-proBNP levels, and that progressive renal dysfunction negatively impacts NT-proBNP levels. Therefore, by excluding patients with progressive renal dysfunction from this analysis, a) the cohort does not match what the real world patient population would look like, and b) the NT-proBNP measurements would seem to be favorably skewed, thereby likely overstating efficacy.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "25d12a96-9745-43ef-b5b3-4b689843fa02",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.78,
        "x": 0.11,
        "y": 0.24
      },
      "kind": "paragraph",
      "text": "In the Phase 1/2 dose escalation study 10 patients were discontinued in the study and 1 patient died.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3e6b6957-005b-4a20-bde3-174a48c60159",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.78,
        "x": 0.11,
        "y": 0.77
      },
      "kind": "paragraph",
      "text": "The Phase 3 dose is 24 mg / kg, which implies that PRTA views 0.5 mg / kg to 4.0 mg / kg doses as sub-therapeutic; however, 50% (four out of eight) patients at these doses experienced organ responses, which calls into question whether the responses were due to PCD treatments or NEOD001.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b6ab424-ba8a-4ea5-85d6-8b2081726748",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.78,
        "x": 0.11,
        "y": 0.32
      },
      "kind": "paragraph",
      "text": "We understand that PRTA published the below graph in 2014. However, it appears to no longer be available on PRTA's website. The graph shows data that we believe belies the notion that NEOD001 is efficacious.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a92027b4-8806-4934-9e99-1bc7b715fd8b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.11,
        "y": 0.89
      },
      "kind": "source-note",
      "text": "16 Palladini et al. J Clinical Oncology; 2012",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e9ec8cd-5123-4e25-9599-e84c1183b215",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.78,
        "x": 0.11,
        "y": 0.28
      },
      "kind": "title",
      "text": "Lack of Correlation Between Doses and Responses in 2014 Sample Patients",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2fb62bfa-671d-4aee-8179-3180027dd46c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 9,
      "from": 3,
      "beatId": "8e48acba-40bb-40b8-a06c-1e96a5fdace0",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The document presents several contradictions and inconsistencies in the trial data, making the problem worse",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}